

# A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy

NCT07241104

---

|            |                 |
|------------|-----------------|
| Status     | RECRUITING      |
| Phase      | Phase 1         |
| Sponsor    | AstraZeneca     |
| Enrollment | 31 participants |

## Key Eligibility Criteria

---

### Inclusion (9)

- Participants must be 18 to 80 years of age inclusive, at the time of Screening
- Participants with pre-existing positive screening for R14 del PLN mutation
- Participants with screening Left ventricular ejection fraction  $\geq$  45% as assessed by echocardiography
- Participants with New York Heart Association (NYHA) function class I-III
- Participants on stable medical therapy for at least 6 weeks prior to Screening and during the Screening period, with no significant improvement in heart failure

... and 4 more (see full listing online)

### Exclusion (34)

- Participants with positive hepatitis C antibody, hepatitis B virus surface antigen or hepatitis B virus core antibody
- Known to have tested positive for Human immunodeficiency virus (HIV)
- Any known genetic mutation associated with hereditary electrical or structural disease
- Congenital long QT syndrome
- QTcF  $<$  350 ms

... and 29 more (see full listing online)

## Locations (4 total)

---

Research Site, Amsterdam, Netherlands  
Research Site, Groningen, Netherlands  
Research Site, Rotterdam, Netherlands  
... and 1 more locations